Keyphrases
Crohn's Disease
100%
Inflammatory Bowel Disease
70%
Acute Diverticulitis
37%
Capsule Endoscopy
25%
Video Capsule Endoscopy
24%
Colonoscopy
23%
Small Intestine
21%
Diverticular Disease
20%
Confidence Interval
19%
Lewis Score
19%
Helicobacter Pylori (H. pylori)
17%
Fecal Calprotectin
17%
Infliximab
17%
Magnetic Resonance Enterography
16%
Inflammation
15%
Endoscopy
13%
Diverticulosis
13%
Early Colonoscopy
13%
Retrospective Cohort Study
13%
Vedolizumab
13%
Clinical Remission
12%
Diverticulitis
12%
Anti-tumor Necrosis Factor (anti-TNF)
12%
Remission
11%
Ulcerative Colitis
11%
PubMed
11%
Active Crohn's Disease
11%
COVID-19
10%
Active Ulcerative Colitis
10%
Small Bowel Inflammation
10%
Patency Capsule
10%
Placebo
10%
Mucosal Inflammation
10%
Odds Ratio
10%
Maintenance Therapy
9%
Colonic Diverticular Disease
9%
Randomized Double-blind
9%
Deep Learning
9%
CT-P13
9%
Crohn's
9%
Clinical Response
8%
Endoscopist
8%
Israel
8%
Mucosal Healing
8%
Risk Factors
7%
SHEBA
7%
Small Bowel Crohn's Disease
7%
Meta-analysis
7%
Systematic Meta-analysis
7%
Colonic Diverticulosis
6%
Medicine and Dentistry
Crohn's Disease
85%
Inflammatory Bowel Disease
52%
Disease
46%
Diverticulum
42%
Capsule Endoscopy
42%
Diverticulitis
41%
Colonoscopy
34%
Endoscopy
23%
Magnetic Resonance Enterography
19%
Ulcerative Colitis
18%
Faecal Calprotectin
18%
Symptom
16%
Helicobacter Pylori
15%
Patient with Crohn's Disease
14%
Patient with Inflammatory Bowel Disease
13%
Retrospective Cohort Study
13%
Diagnosis
12%
Systematic Review
12%
Infliximab
12%
Odds Ratio
12%
Biological Marker
12%
Diffusion MRI
10%
Placebo
9%
Ankylosing Spondylitis
9%
Vedolizumab
9%
Prevalence
9%
Colitis
9%
Gastroenterology
9%
Disease Exacerbation
8%
Cohort Analysis
7%
Microbiome
7%
Meta-Analysis
7%
Colon
6%
Prospective Cohort Study
6%
Neoplasm
6%
Maintenance Therapy
6%
Adverse Event
6%
Colon Diverticulosis
6%
Biological Product
6%
Etrolizumab
6%
Telemedicine
6%
Coronavirinae
6%
Disease Activity
6%
Prospective Study
6%
Crohn's Disease Activity Index
5%
Combination Therapy
5%
Stricture
5%
Abdominal Pain
5%
Quality of Life
5%
Anal Fistula
5%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
68%
Inflammatory Bowel Disease
40%
Diverticulitis
26%
Ulcerative Colitis
25%
Remission
22%
Disease
22%
Inflammation
17%
Placebo
17%
Infliximab
14%
Helicobacter Pylori
12%
Symptom
12%
Diverticulosis
11%
Cohort Study
10%
Disease Activity
10%
Randomized Controlled Trial
9%
Adverse Event
9%
Prevalence
9%
Colitis
9%
Calgranulin
9%
Biological Marker
8%
Tumor Necrosis Factor
7%
Coronavirinae
7%
Immunogenicity
6%
Curcumin
6%
Vedolizumab
6%
Etrolizumab
6%
Janus Kinase Inhibitor
6%
Neoplasm
6%
Biological Product
5%
Cannabis
5%
Combination Therapy
5%
Pharmacokinetics
5%
Ustekinumab
5%